Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A 20-valent Pneumococcal Conjugate Vaccine In Pneumococcal Vaccine-naive Adults 18 Years Of Age And Older

Trial Profile

A Phase 3, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A 20-valent Pneumococcal Conjugate Vaccine In Pneumococcal Vaccine-naive Adults 18 Years Of Age And Older

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs PF 06482077 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
  • Indications Pneumococcal infections; Pneumonia
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 29 Nov 2018 Status changed from planning to not yet recruiting.
    • 26 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top